Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems

Alzhrani, Rami M.; Alsaab, Hashem O.; Petrovici, Alex; Bhise, Ketki; Vanamala, Kushal; Sau, Samaresh; Krinock, Matthew J.; Iyer, Arun K.

doi:10.1016/j.drudis.2019.11.006

Cited by 42 publications

(20 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Noncoding RNAs (ncRNAs) are RNAs that account for nearly 98% of transcriptome 21 . According to length and shapes, ncRNAs are divided into various types including microRNAs (miRNAs), PIWI-interacting RNAs (piRNAs), small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), long ncRNAs (lncRNAs), circular RNAs (circRNAs), transfer RNAs (tRNAs), and ribosomal RNAs (rRNAs) 22 , 23 . NcRNAs participate in regulation of tumorigenesis via various biological processes such as chromatin modification, alternative splicing, competition with endogenous RNAs and interaction with proteins 24 , 25 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression

Zhang

Wang

et al. 2020

Cell Death Dis

View full text Add to dashboard Cite

Cancer progression including proliferation, metastasis, and chemoresistance has become a serious hindrance to cancer therapy. This phenomenon mainly derives from the innate insensitive or acquired resistance of cancer cells to apoptosis. Ferroptosis is a newly discovered mechanism of programmed cell death characterized by peroxidation of the lipid membrane induced by reactive oxygen species. Ferroptosis has been confirmed to eliminate cancer cells in an apoptosis-independent manner, however, the specific regulatory mechanism of ferroptosis is still unknown. The use of ferroptosis for overcoming cancer progression is limited. Noncoding RNAs have been found to play an important roles in cancer. They regulate gene expression to affect biological processes of cancer cells such as proliferation, cell cycle, and cell death. Thus far, the functions of ncRNAs in ferroptosis of cancer cells have been examined, and the specific mechanisms by which noncoding RNAs regulate ferroptosis have been partially discovered. However, there is no summary of ferroptosis associated noncoding RNAs and their functions in different cancer types. In this review, we discuss the roles of ferroptosis-associated noncoding RNAs in detail. Moreover, future work regarding the interaction between noncoding RNAs and ferroptosis is proposed, the possible obstacles are predicted and associated solutions are put forward. This review will deepen our understanding of the relationship between noncoding RNAs and ferroptosis, and provide new insights in targeting noncoding RNAs in ferroptosis associated therapeutic strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

“…CircRNAs are covalently closed, single-stranded RNA molecules derive from exons via alternative mRNA splicing 22 . Several studies have uncovered function of circRNAs in ferroptosis.…”

Section: Introductionmentioning

confidence: 99%

Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression

Zhang

Wang

et al. 2020

Cell Death Dis

View full text Add to dashboard Cite

show abstract

“…Angiogenic inhibitors can be loaded on/within nanocarriers by encapsulation or chemical conjugation, to be delivered passively or actively to the tumor cells. A study showed that nanoparticle-conjugated chemotherapeutic agents such as doxorubicin (DOX) and small antiangiogenic molecules could preferentially home in on tumors using an enhanced permeability and retention effect (EPR) that results in tumor growth inhibition and selective vascular shutdown [78,79].…”

Section: Synergistic Antiangiogenetic Activity With Chemotherapymentioning

confidence: 99%

Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine

Alsaab

Al-Hibs

Alzhrani

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Angiogenesis is one of the hallmarks of cancer. Several studies have shown that vascular endothelium growth factor (VEGF) plays a leading role in angiogenesis progression. Antiangiogenic medication has gained substantial recognition and is commonly administered in many forms of human cancer, leading to a rising interest in cancer therapy. However, this treatment method can lead to a deteriorating outcome of resistance, invasion, distant metastasis, and overall survival relative to its cytotoxicity. Furthermore, there are significant obstacles in tracking the efficacy of antiangiogenic treatments by incorporating positive biomarkers into clinical settings. These shortcomings underline the essential need to identify additional angiogenic inhibitors that target numerous angiogenic factors or to develop a new method for drug delivery of current inhibitors. The great benefits of nanoparticles are their potential, based on their specific properties, to be effective mechanisms that concentrate on the biological system and control various important functions. Among various therapeutic approaches, nanotechnology has emerged as a new strategy for treating different cancer types. This article attempts to demonstrate the huge potential for targeted nanoparticles and their molecular imaging applications. Notably, several nanoparticles have been developed and engineered to demonstrate antiangiogenic features. This nanomedicine could effectively treat a number of cancers using antiangiogenic therapies as an alternative approach. We also discuss the latest antiangiogenic and nanotherapeutic strategies and highlight tumor vessels and their microenvironments.

show abstract

“…Over the last two decades our molecular understanding of RNA interference (RNAi) and the technology to deliver oligonucleotides in vivo has grown exponentially [1] . The growing appeal of using RNAi technology as therapeutics is based, in large part, on the potential to achieve highly specific, rationally designed therapies based on the primary sequence of the targeted transcripts.…”

mentioning

confidence: 99%

“…These observations highlight how novel RNAi-mediated mechanisms of cell fate regulation can combine with nanomedicine to provide new avenues to develop innovative molecular therapeutics. Thus far, two siRNA-based therapeutics have been approved by the Food and Drug Administration (FDA) to treat hereditary transthyretin amyloidosis (Patisiran) and acute hepatic porphyria (Givosiran) [ 9 , 10 ] with several others currently in clinical trials [1] . The positive momentum from the clinical success of siRNA-based drugs are paving the way for clinical trials to test miRNA-based therapeutics.…”

mentioning

confidence: 99%

Opinion: miRNAs – The new wave of molecular cancer therapeutics

López-Bertoni

Laterra

2021

Translational Oncology

View full text Add to dashboard Cite

Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics. In this perspective, we will briefly discuss how miRNAs are becoming the next-generation RNAi therapeutic, the advances in delivery vehicles for in vivo miRNA delivery, and where miRNA technology stands in terms of clinical translation.

show abstract

Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems

Cited by 42 publications

References 139 publications

Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression

Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression

Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine

Opinion: miRNAs – The new wave of molecular cancer therapeutics

Contact Info

Product

Resources

About